Form 4: Jasper Therapeutics CFO Granted 90,000 Stock Options

Jasper Therapeutics' Chief Financial Officer, Herb Cross, was granted 90,000 stock options with an exercise price of $1.84, vesting over four years.

Summary

• Herb Cross, Chief Financial Officer of Jasper Therapeutics, Inc. (JSPR), was granted 90,000 stock options.
• The options have an exercise price of $1.84 per share.
• The grant date for these options was January 2, 2026.
• The options will vest over time, with 1/4th vesting on January 2, 2027, and an additional 1/48th of the original number of shares vesting each month thereafter.
• Vesting is contingent upon Mr. Cross's continuous service to the Issuer.
• The options expire on January 2, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant), which is generally a neutral to slightly positive signal as it aligns management incentives with shareholder interests, but does not reflect operational or financial performance.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The establishment of a Rule 10b5-1(c) plan indicates a pre-arranged and transparent approach to executive compensation and potential future transactions.

Future Outlook

The vesting schedule of the stock options, extending through monthly increments after the initial one-year cliff, indicates an expectation of continued service from the Chief Financial Officer and aims to incentivize long-term commitment and performance.

Industry Context

The grant of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industry, including companies like Jasper Therapeutics, to attract, retain, and motivate talent. This compensation structure is designed to align executive interests with long-term shareholder value creation, particularly in a sector characterized by long development cycles and significant R&D investments.

Comparison to Industry Standards

• The grant of stock options as a component of executive compensation is a common practice across the biotechnology and broader technology sectors, comparable to compensation structures seen at companies like Moderna, BioNTech, or smaller clinical-stage biotechs.
• A four-year vesting schedule with a one-year cliff is a typical industry standard for executive equity grants, designed to ensure executive retention and long-term commitment, similar to plans observed at companies such as Gilead Sciences or Amgen for their senior leadership.

Corporate Governance

Related Party Transactions

• The grant of stock options to Herb Cross, the Chief Financial Officer, constitutes a transaction between the company and a key executive, which is a form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The stock option grant aims to align the CFO's financial interests with long-term shareholder value creation, potentially leading to more focused management decisions.
• Employees: This type of executive compensation can set a precedent or standard for other employee incentive programs, potentially impacting morale and retention.

Next Steps

• Herb Cross's continued service to the Issuer is required for the options to vest according to the schedule.

Key Dates

Keywords

Jasper Therapeutics, JSPR, Stock Options, Executive Compensation, Form 4, Insider Transaction, Herb Cross, CFO, Vesting, Rule 10b5-1